This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GFI1 / Zinc finger protein Gfi-1 · IHC design guide
Design Immunohistochemistry for GFI1
Plan chromogenic IHC for GFI1 using its reported nuclear tissue pattern (HPA tissue IHC) and an IHC-validated antibody. Compare nuclear staining in bone marrow hematopoietic cells (HPA tissue IHC), while accounting for the reported low consistency between antibody staining and RNA expression (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
GFI1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | General nuclear staining (HPA tissue IHC) | |
| Staining pattern | High nuclear staining in bone marrow hematopoietic cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A00888-1) | |
| Positive control | Bone marrow+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Bone marrow/lymphoid RNA enriched (HPA tissue RNA) | |
| Isoform / epitope | No isoforms annotated; one 1–422 chain (UniProt) |
Section 1
Recommended GFI1 IHC & IF Protocols
The catalog antibody protocol uses citrate pH 6 heat retrieval (datasheet A00888-1). The published cartilage and knee joint IHC protocol below uses trypsin retrieval (PMC12332208).
| Sample | Paraffin-embedded human mammary cancer tissue; fixative not specified (datasheet A00888-1) |
| Fixation | Image fixative and duration unreported (datasheet A00888-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A00888-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00888-1) |
| Primary antibody | Rabbit anti-GFI1, 1μg/ml (datasheet A00888-1) |
| Primary incubation | Overnight at 4 °C (datasheet A00888-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A00888-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | GFI1-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: High). HPA tissue profile: General nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6 heat retrieval for the catalog antibody (datasheet A00888-1); consider trypsin retrieval for cartilage or knee joint sections (PMC12332208).
Section 2
What Is the Expected GFI1 Staining Pattern?
GFI1 should appear mainly in nuclei: UniProt places it in the nucleus and reports no transmembrane segment (UniProt Q99684: subcellular location; topology). HPA reports general nuclear IHC staining, including high staining in bone marrow hematopoietic cells and cerebellar granular-layer cells (HPA: tissue IHC). Treat this as a provisional expectation because the tissue pattern has Uncertain reliability and the listed IHC antibody has Uncertain validation (HPA: tissue reliability; CAB011197 IHC).
| Distinct nuclear staining in bone marrow hematopoietic cells, with restrained surrounding background. | This fits the reported compartment and a high-staining cell population (UniProt Q99684: nucleus; HPA: High in bone marrow hematopoietic cells). Compare nuclei and adjacent areas on the same section; a plausible pattern alone does not resolve the Uncertain HPA antibody validation (HPA: CAB011197 IHC). |
| Predominantly cytoplasmic, membranous, or extracellular brown staining while nuclei remain pale. | That distribution conflicts with the reported nuclear location and lack of a transmembrane segment (UniProt Q99684: subcellular location; topology). Review morphology and detection controls before interpreting it as GFI1; widespread staining outside nuclei can reflect nonspecific binding or detection artefact (general IHC practice). |
| Strong staining in an unexpected cell population, especially when its nuclei do not carry the signal. | HPA reports high staining in named cell populations, but gives no negative tissue category and rates the IHC pattern Uncertain (HPA: tissue IHC; reliability). Check cell identity and a no-primary control; cross-reactivity or endogenous detection activity are possible explanations, not conclusions from this slide alone (general IHC practice). |
| Diffuse haze across tissue and background, with poor separation between nuclei and their surroundings. | A broad haze is difficult to reconcile with the reported nuclear pattern (HPA: general nuclear expression; UniProt Q99684: nucleus). Inspect the no-primary control and compare background across sections; antibody concentration, blocking, washing, or chromogen development can affect contrast (general IHC practice). |
| No convincing nuclear signal in bone marrow hematopoietic cells despite intact tissue morphology. | HPA reports high staining in these cells, making them a useful comparison, though the report is Uncertain rather than a guaranteed positive control (HPA: High in bone marrow hematopoietic cells; tissue reliability). Check the IHC workflow and a successful detection control before assigning biological absence (general IHC practice). |
💡Expected GFI1 appearanceCall a result provisionally positive when discrete nuclear signal appears in bone marrow hematopoietic cells, where HPA reports high staining; broad cytoplasmic or background signal is suspect (UniProt Q99684: nucleus; HPA: High in bone marrow hematopoietic cells; HPA: Uncertain IHC reliability).
| Compartment and cell context | UniProt places GFI1 in the nucleus and notes colocalization with PIAS3 and RUNX1T1 in nuclear dots; HPA describes general nuclear IHC expression (UniProt Q99684: subcellular location; HPA: tissue IHC). Evaluate nuclear signal in identified cells rather than scoring a whole tissue section by color alone (general IHC practice). |
| Strength of tissue evidence | HPA lists high staining in several populations, including bone marrow hematopoietic cells and cerebellar granular-layer cells, but rates tissue IHC reliability Uncertain because antibody staining has low consistency with RNA data (HPA: tissue IHC; reliability). High staining guides selection of comparison tissue; it does not establish specificity. |
| Low staining versus absence | HPA lists low staining in pancreatic exocrine glandular cells, vaginal squamous epithelial cells, soft-tissue fibroblasts, and adipocytes, and lists no negative category (HPA: tissue IHC). These populations may help assess relative contrast; none is an established GFI1-negative control. |
| Protein features and preparation limits | UniProt reports no transmembrane segment, signal peptide, propeptide, or annotated isoforms, and records phosphoserines at positions 20 and 56 (UniProt Q99684: topology; processing; isoforms; modified residues). These annotations do not identify the antibody epitope or establish retrieval needs or fixation sensitivity. |
| Situation | Likely cause | Next action |
|---|---|---|
| Nuclear staining is weak or absent in bone marrow hematopoietic cells. | Low signal may reflect a workflow issue; HPA's high-staining report is an Uncertain reference, not proof that every section must stain (HPA: tissue IHC; reliability). | Confirm tissue identity and detection performance, then review the catalog antibody's IHC-P instructions for its specified dilution and retrieval conditions; do not infer a GFI1-specific fixation effect (general IHC practice). |
| Brown product fills cytoplasm or outlines membranes more strongly than nuclei. | The dominant compartment disagrees with the reported nuclear location and no-transmembrane topology (UniProt Q99684: subcellular location; topology). | Compare nuclear counterstain with chromogen placement and inspect no-primary and detection controls; adjust staining conditions only after identifying the source of the misplaced signal (general IHC practice). |
| Most of the section is hazy, obscuring individual positive cells. | Excess background can arise during antibody incubation, blocking, washing, or chromogen development (general IHC practice). | Use a no-primary control to locate detection background, then review dilution, blocking, wash steps, and development time against the chosen IHC-P workflow (general IHC practice). |
| Unexpected cells stain strongly, or a low-staining comparison tissue looks as strong as bone marrow. | HPA lists specific high and low cell populations but no negative category; its IHC reliability is Uncertain (HPA: tissue IHC; reliability). The pattern may reflect biology, cell misidentification, or nonspecific signal. | Verify cell morphology, compare like compartments, and inspect no-primary staining before calling cross-reactivity; seek an independent specificity check if the result drives a biological conclusion (general IHC practice). |
| No-primary control is positive. | Signal without primary antibody can arise from endogenous detection activity or detection reagents (general IHC practice). | Identify whether signal tracks endogenous enzyme activity or reagent background, then apply the appropriate blocking or detection-system adjustment for the chromogenic method (general IHC practice). |
| Can an IF/ICC image confirm this IHC pattern? | HPA supplies no GFI1 ICC-IF images or main-location assignment; its tissue IHC profile describes general nuclear expression (HPA: subcellular record; tissue IHC). | Use the IHC tissue pattern as the provisional reference here. Assess IF/ICC on its own guide page and avoid treating the absent HPA ICC-IF images as validation (HPA: subcellular record; general IHC/IF practice). |
Experiment evidence
IHC & IF images showing GFI1 staining
A00888-1 · IHCIHC analysis of GFI1 using anti-GFI1 antibody (A00888-1). GFI1 was detected in paraffin-embedded section of human mammary cancer tissue. Hea
A00888-1 · IHCIHC analysis of GFI1 using anti-GFI1 antibody (A00888-1). GFI1 was detected in paraffin-embedded section of human rectal cancer tissue. Heat
A00888-3 · IHCIHC analysis of GFI1 using anti-GFI1 antibody (A00888-3). GFI1 was detected in paraffin-embedded section of human rectal cancer tissue. Heat
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/cerebral+cortex#imid_3184080
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/colon#imid_3184014
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/liver#imid_3184023
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/kidney#imid_3184016
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for GFI1 IHC & IF
🧪Run bone marrow first and assess nuclear staining in hematopoietic cells (HPA: High in bone marrow hematopoietic cells; UniProt Q99684: nucleus). HPA detects GFI1 in all 45 scored tissues, so no negative tissue is available; use no-primary and isotype controls, and treat cells without nuclear signal on the positive slide as a background comparison rather than a validated negative cell population (HPA: no negative rows).
Positive control tissue: Bone marrow (Hematopoietic cells, HPA High)
Negative control tissue: None in HPA: GFI1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for GFI1; derive a cell-line control from the positive tissue's cell type (Hematopoietic cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control, a concentration-matched rabbit IgG isotype control for the rabbit catalog antibody, and GFI1-knockout material where available as a biological negative (caption: rabbit anti-GFI1 antibody; standard IHC practice). For bone marrow DAB staining, quench endogenous peroxidase and block endogenous biotin when using the caption’s biotin-based detection system (HPA: bone marrow hematopoietic cells; caption: biotinylated secondary, streptavidin–biotin complex, DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A00888-1 paraffin-section caption does not state a fixative (caption: fixative not stated). The caption uses citrate retrieval at pH 6 for 20 minutes, but does not establish whether retrieval is required for all specimens or whether frozen sections or IF are easier (caption: heat-mediated citrate retrieval; HPA: no ICC-IF images listed). Endogenous peroxidase in bone marrow hematopoietic cells can complicate DAB interpretation, so assess staining against the peroxidase-quenched controls (HPA: bone marrow hematopoietic cells; caption: DAB detection; standard IHC practice).
HPA tissue IHC evidence for GFI1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: GFI1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced GFI1 IHC Tips
Troubleshoot nuclear GFI1 staining in paraffin sections while treating tissue patterns as provisional (UniProt Q99684 localisation; HPA: Uncertain).
What retrieval should I start with when nuclear GFI1 staining is weak?
Start with heat mediated antigen retrieval in citrate buffer at pH 6 for 20 minutes (datasheet A00888-1). In the documented paraffin section workflow, the catalog antibody was applied at 1 μg/mL overnight at 4°C; keep those conditions fixed while assessing retrieval (datasheet A00888-1). Compare a retrieved section with a section processed without retrieval, using the same detection and development times, to identify retrieval dependent signal (standard IHC practice). If nuclear staining remains weak, adjust heating time in small increments on matched sections and check tissue preservation before trying another buffer as a fallback (standard IHC practice; UniProt Q99684 localisation).
Could fixation explain weak or uneven GFI1 staining?
The selected paraffin section caption does not state a fixative, so target specific GFI1 sensitivity to fixation is unknown (datasheet A00888-1). Record the actual fixative, fixation duration, section thickness, and storage history for each specimen before comparing staining intensity (standard IHC practice). On matched sections, hold citrate retrieval at pH 6 for 20 minutes and the antibody at 1 μg/mL overnight at 4°C, then compare batches for nuclear signal and morphology (datasheet A00888-1; standard IHC practice). Do not assign a fixation effect from the HPA tissue pattern or from GFI1 topology and phosphorylation alone (HPA: Uncertain; UniProt Q99684 topology and modified residues).
How should I assess cytoplasmic staining when GFI1 is expected in nuclei?
Score nuclear staining as the expected compartment because GFI1 is annotated in the nucleus, including nuclear dots with PIAS3 and RUNX1T1 (UniProt Q99684 localisation). Examine a counterstained section at high magnification to distinguish nuclear signal from cytoplasmic haze or chromogen deposited over adjacent cells (standard IHC practice). Compare nuclear and cytoplasmic staining in the same region, alongside a no primary control, before accepting a compartment shift (standard IHC practice). GFI1 has no annotated transmembrane segment, so a crisp membrane pattern needs independent validation rather than interpretation as expected GFI1 localisation (UniProt Q99684 topology and localisation).
How can I troubleshoot discrepant staining from antibodies to different GFI1 epitopes?
GFI1 is recorded as a 422 amino acid chain with no annotated isoforms, but the supplied evidence does not map this antibody’s epitope (UniProt Q99684 processing and isoforms; datasheet A00888-1). Its listed phosphoserines at positions 20 and 56 make modification status a consideration only if an antibody’s mapped epitope includes those sites (UniProt Q99684 modified residues; standard IHC practice). Compare antibodies on adjacent sections under their own validated retrieval conditions, then check whether the same cells show nuclear staining (standard IHC practice; UniProt Q99684 localisation). Treat disagreement as unresolved until epitope information and appropriate controls support an explanation; absence of annotated isoforms does not establish identical epitope accessibility (UniProt Q99684 isoforms; standard IHC practice).
How should I check an IF result alongside chromogenic GFI1 IHC?
Treat IF as a separate assay: the supplied catalog example documents paraffin section IHC, and HPA lists no cell lines with ICC/IF images here (datasheet A00888-1; HPA subcellular). For multiplexing, pair GFI1 with a validated marker of the cell population under study and assess nuclear colocalisation in single channel images (standard IF practice; UniProt Q99684 localisation). Choose fluorophores whose emission can be separated from the specimen’s autofluorescence, using unstained and single stain controls to set exposure and check bleed through (standard IF practice). Because GFI1 is nuclear and has no transmembrane segment, optimise permeabilisation for access to the nuclear epitope, while confirming that nuclear morphology remains intact (UniProt Q99684 localisation and topology; standard IF practice).
What controls distinguish GFI1 signal from chromogenic background?
The documented IHC workflow uses 10% goat serum blocking, a biotinylated secondary, streptavidin biotin detection, and DAB (datasheet A00888-1). Run no primary and secondary only controls to test nonspecific secondary binding and detection background, then assess an endogenous biotin control if staining persists (standard IHC practice; datasheet A00888-1 detection). Include a peroxidase block and inspect the no primary section for residual enzyme associated DAB deposition; these are general chromogenic IHC controls, not GFI1 specific validation (standard IHC practice). If background remains, optimise blocking, washing, antibody concentration, and DAB development one variable at a time while preserving interpretable nuclear signal (standard IHC practice; UniProt Q99684 localisation).
How should I quantify GFI1 staining across specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and tissue region before scoring, then record the percentage of nuclei positive for GFI1 and, if intensity is reproducible, a nuclear H score (standard IHC practice; UniProt Q99684 localisation). For sparse populations, report positive nuclei per mm² of viable tissue and the total eligible nuclei examined, rather than a field count alone (standard IHC practice). Normalise each comparison to the same eligible cell type or viable tissue area, with matched staining and imaging settings across sections (standard IHC practice). Report thresholds and exclusion rules for necrosis, folds, and section edges, and qualify comparisons because HPA rates tissue IHC reliability as uncertain (standard IHC practice; HPA: Uncertain).
When is a GFI1 positive cell convincing rather than an artefact?
A convincing candidate shows nuclear staining in an intact cell, consistent with GFI1’s annotated nuclear localisation and the HPA general nuclear profile (UniProt Q99684 localisation; HPA: general nuclear expression). Bone marrow hematopoietic cells are reported with high staining, but HPA labels its tissue IHC reliability uncertain because staining and RNA data have low consistency (HPA: High in bone marrow hematopoietic cells; HPA: Uncertain). Check cell identity and exclude edge accentuation, necrotic deposits, and isolated cytoplasmic or membrane staining before counting positives (standard IHC practice; UniProt Q99684 localisation and topology). Compare no primary and peroxidase blocked controls when DAB appears in unexpected cells, since endogenous enzyme activity can mimic chromogenic signal (standard IHC practice).
Boster reagents
Best GFI1 / Zinc finger protein Gfi-1 IHC Antibodies
Two anti-GFI1 antibodies have human paraffin-section IHC images; both list human, mouse, and rat reactivity, and neither has an IF image (catalog reactivity and image alts).
Real IHC data
Anti-GFI1 Antibody
Cat # A00888-1
Real IHC data
Anti-GFI1 Antibody ®
Cat # A00888-3
A00888-1 is listed for IHC and pictured on human mammary and rectal cancer paraffin sections (catalog applications; A00888-1 image alts). A00888-3 is listed for IHC and pictured on a human rectal cancer paraffin section (catalog applications; A00888-3 image alt).
Which to pick: For paraffin-section IHC, choose A00888-1 for its pictured citrate retrieval at pH 6, or A00888-3 for its pictured EDTA retrieval at pH 8 (each SKU’s IHC image alt). Neither is an IF/ICC-validated pick: IF/ICC is absent from both application lists and neither has an IF image (catalog applications and IF image alts). For mouse or rat IHC, both list reactivity, but their IHC images show human tissue; A00888-1 is polyclonal, A00888-3 has no stated clonality, and neither caption reports the fixative (catalog reactivity, dilution_raw, and IHC image alts).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q99684 (GFI1_HUMAN, Zinc finger protein Gfi-1).
- Human Protein Atlas. GFI1 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. GFI1 subcellular location (ICC-IF): Highest expression in THP-1: 231.3 nTPM.
- Human Protein Atlas. GFI1 antibody validation summary (1 antibodies).
- Growth Factor Independence-1 (Gfi1) Is Required for Pancreatic Acinar Unit Formation and Centroacinar Cell Differentiation. Cellular and molecular gastroenterology and hepatology 2015 — PMC5301134.
- GFI1 promotes the proliferation and migration of esophageal squamous cell carcinoma cells through the inhibition of SOCS1 expression. International journal of molecular medicine 2021 — PMC8416140.
- SAM pointed domain ETS factor (SPDEF) regulates terminal differentiation and maturation of intestinal goblet cells. Experimental cell research 2010 — PMC3004755.
- Growth factor independence 1 ameliorates osteoarthritis by inhibiting chondrocyte ferroptosis via inactivation of MAPK signaling pathway. Journal of orthopaedic translation 2025 — PMC12332208.
- PubMed PMID:9051000 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:8754800 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for GFI1 (Zinc finger protein Gfi-1). Expected localisation General nuclear staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A00888-1). Validated IHC antibody: A00888-1 at 1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bone marrow (Hematopoietic cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human mammary cancer tissue; fixative not specified (datasheet A00888-1); 2. Fixation: Image fixative and duration unreported (datasheet A00888-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A00888-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00888-1); 8. Primary antibody: Rabbit anti-GFI1, 1μg/ml (datasheet A00888-1); 9. Primary incubation: Overnight at 4 °C (datasheet A00888-1). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: No isoforms annotated; one 1–422 chain (UniProt); Regulation: Bone marrow/lymphoid RNA enriched (HPA tissue RNA). Evidence: UniProt Q99684, HPA tissue IHC · Uncertain, HPA cell-line RNA · Highest expression in THP-1: 231.3 nTPM, Datasheet A00888-1, PMC12332208. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/GFI1/immunohistochemistry-ihc-guide.